What question did this study set out to answer?

To assess the antihypertensive efficacy of the angiotensin-converting enzyme inhibitor SQ 20,881 in patients with severe hypertension.

January 1, 1974Clinical Science

Treatment of Patients with Severe Hypertension by Inhibition of Angiotensin-Converting Enzyme

View Full Paper

Ask AI

Bookmark

Why the study?

Does the nona-peptide ACE inhibitor SQ 20,881 reduce blood pressure in patients with severe hypertension?

Population

12 patients with severe hypertension

Design

Case_series

Authors

JJJames G. JohnsonChicago Zoological Society WBW D BlackUniversity of Guelph RVR. A. VukovichBaptist Memorial Hospital

Discussion

Member takes

Implication

Should not yet change practice in severe hypertension; leaves open the need for randomized confirmation of ACE inhibition.

Key Points

To assess the antihypertensive efficacy of the angiotensin-converting enzyme inhibitor SQ 20,881 in patients with severe hypertension.
Administered the nonapeptide ACE inhibitor SQ 20,881 (doses up to 2 mg/kg) to 12 patients with severe hypertension.
Categorized patients by baseline plasma renin activity (PRA; normal at 1.6–3.7 ng h⁻¹ ml⁻¹ vs. high at 5.0–74 ng h⁻¹ ml⁻¹) and evaluated response modifications following frusemide diuresis, haemodialysis, or altered blood volume.
SQ 20,881 administration resulted in blood pressure reduction in 10 of 12 patients, including all 8 patients with high PRA and 2 of 4 patients with normal PRA.
Haemodialysis and frusemide diuresis enhanced the hypotensive response to the inhibitor, while low total blood volume produced an exaggerated blood pressure drop at a reduced dose (0.125 mg/kg).

Structured PICO

Does the nona-peptide ACE inhibitor SQ 20,881 reduce blood pressure in patients with severe hypertension?

Population

12 patients with severe hypertension

Intervention

Nona-peptide inhibitor (SQ 20,881) of angiotensin-converting enzyme (doses up to 2 mg/kg)

Outcome

Fall in blood pressuresurrogate

Inhibition of angiotensin-converting enzyme with SQ 20,881 effectively lowers blood pressure in most patients with severe hypertension, regardless of baseline plasma renin activity.

Cite This Study

Johnson et al. (1974) studied this question.

synapsesocial.com/papers/6a744ef0fd85dc9184090508 https://doi.org/10.1042/cs048053s

View Full Paper

Ask AI

Bookmark

Treatment of Patients with Severe Hypertension by Inhibition of Angiotensin-Converting Enzyme

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Treatment of Patients with Severe Hypertension by Inhibition of Angiotensin-Converting Enzyme

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider